ACET News and Press, Adicet Bio Inc.

2024-07-08 11:31:42 ET More on Adicet Bio Adicet Bio: Microcap With A High Risk To Reward Ratio FDA clears IND application for Adicet Bio’s CAR T cell therapy candidate Adicet Bio gains on FDA fast track designation for ADI-001 in lupus nephritis Seeki...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-270 for the potentia...

2024-06-24 09:03:53 ET Adicet Bio ( NASDAQ: ACET ) shares gained in early trading on Monday after the U.S. drug regulator cleared the company’s Investigational New Drug (IND) application to evaluate its CAR T cell therapy candidate, ADI-270, in relapsed/refractory renal c...

2024-06-05 07:45:31 ET More on Adicet Bio Adicet Bio: Microcap With A High Risk To Reward Ratio Adicet Bio GAAP EPS of -$0.69 beats by $0.01 Seeking Alpha’s Quant Rating on Adicet Bio Historical earnings data for Adicet Bio Financial informatio...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potentia...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferi...

2024-05-23 11:06:03 ET Summary Adicet Bio is a biotech company focused on developing off-the-shelf cell therapies for cancer and autoimmune diseases. They are currently conducting a phase 1 trial for their pilot cell therapy, ADI-001, targeting B-cell non-Hodgkin's lymphomas. ...

2024-05-14 17:09:36 ET More on Adicet Bio Adicet Bio GAAP EPS of -$0.69 beats by $0.01 Seeking Alpha’s Quant Rating on Adicet Bio Historical earnings data for Adicet Bio Financial information for Adicet Bio Read the full article on Seeking Al...

On track to initiate Phase 1 clinical trial evaluating ADI-001 in lupus nephritis in 2Q 2024 Presented promising preclinical data on ADI-270 at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting; on track to file investigational new drug (IND) in renal cell carcinoma in ...

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced the acceptance of a poster presentation at the upcoming European Hematology Association (EHA) Hybrid Congr...